Hinge Health (HNGE) Stock Looks Fairly Valued As Its 66% Run Continues
After a strong 65.8% gain over the past year, Hinge Health no longer looks like an obvious bargain, and the valuation checks now lean toward a stock that is closer to fairly priced than clearly cheap.
- Hinge Health has delivered a 65.8% return over the last 12 months, which puts added scrutiny on whether the current price still leaves enough room for further upside.
- Future revenue growth and progress toward stronger cash flow can support the current valuation, while any setback in scaling the business model or controlling costs may quickly weigh on what investors are willing to pay.
- On Simply Wall St's broader valuation checks, Hinge Health passes only 2 out of 6 tests, which points to a stock that currently leans expensive rather than a clear-cut value opportunity.
The issue now is whether Hinge Health's recent share price strength already reflects the main positives investors are counting on, or if the current valuation still leaves a reasonable margin of safety.
Is Hinge Health Fairly Priced on Sales?
The P/S ratio is usually a better fit for Hinge Health because the company is still building toward stronger profitability. Revenue gives a clearer base to compare against. Right now Hinge Health trades on a P/S of about 9.0x, which is higher than the Healthcare industry average of around 1.5x and also above the peer group average of about 6.1x.
The fair P/S multiple that blends in Hinge Health's growth profile, margins, size and risk is estimated at roughly 8.3x. That sits only slightly below the current 9.0x level. This suggests the stock is not extremely cheap or stretched on this measure. The current price asks investors to pay a premium to the industry and peers, but it is broadly in line with what this model suggests is reasonable for the company.
On the P/S multiple, Hinge Health stock appears to be priced roughly in line with what the underlying model suggests is fair.
See what the numbers say about this price — find out in our valuation breakdown.
The Hinge Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Hinge Health's valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price on the Community page. Each Narrative links a specific story about Hinge Health's potential catalysts and risks to an implied fair value, so you can see over time which version of events seems closest to reality.
Community views on Hinge Health sit far apart, with one camp seeing meaningful upside potential and another focused on how much future success is already priced in.
Bull case: 17% undervalued
"Expansion of integrated digital and in person offerings through HingeSelect and broader provider network build out positions the company to pursue a larger share of MSK and adjacent care pathways…"
Read the full Bull Case to see why Hinge Health could be undervalued
Bear case: 16% overvalued
"Although HingeSelect is positioned around high quality providers and lower cost care, it is a multi year buildout of a two sided network."
Read the full Bear Case to see why Hinge Health could be overvalued
Do you think there's more to the story for Hinge Health? Head over to our Community to see what others are saying!
The Bottom Line
For Hinge Health, the current P/S based view suggests the stock now sits closer to fairly priced than clearly undervalued. The market is already asking you to pay a premium to the wider healthcare sector, and the broader valuation checks remain on the weak side, even if the tailored multiple looks about right. From here, the key question is whether Hinge Health can deliver the revenue growth and margin progress that keep justifying that premium, without leaving you paying up for expectations that are already fully reflected in the price.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com